Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Guan, Qiang
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease. [electronic resource] - The International journal of neuroscience Jun 2010 - 421-7 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1563-5279
10.3109/00207451003797694 doi
Animals
Antiparasitic Agents--adverse effects
Corpus Striatum--drug effects
Cyclin-Dependent Kinase 5--antagonists & inhibitors
Disease Models, Animal
Dopamine and cAMP-Regulated Phosphoprotein 32--metabolism
Dyskinesia, Drug-Induced--complications
Female
Levodopa--adverse effects
Male
Oxidopamine
Parkinsonian Disorders--complications
Phosphorylation--drug effects
Protein Kinase Inhibitors--therapeutic use
Purines--therapeutic use
Random Allocation
Rats
Rats, Sprague-Dawley
Roscovitine
Severity of Illness Index
Treatment Outcome
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease. [electronic resource] - The International journal of neuroscience Jun 2010 - 421-7 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1563-5279
10.3109/00207451003797694 doi
Animals
Antiparasitic Agents--adverse effects
Corpus Striatum--drug effects
Cyclin-Dependent Kinase 5--antagonists & inhibitors
Disease Models, Animal
Dopamine and cAMP-Regulated Phosphoprotein 32--metabolism
Dyskinesia, Drug-Induced--complications
Female
Levodopa--adverse effects
Male
Oxidopamine
Parkinsonian Disorders--complications
Phosphorylation--drug effects
Protein Kinase Inhibitors--therapeutic use
Purines--therapeutic use
Random Allocation
Rats
Rats, Sprague-Dawley
Roscovitine
Severity of Illness Index
Treatment Outcome